An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 08 Jul 2017
At a glance
- Drugs Ribociclib (Primary) ; Trastuzumab; Trastuzumab emtansine
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Jun 2017 Trial design of phase Ib part, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 02 Apr 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 01 Feb 2016 New trial record